CoChat
Sign Up
Cited by 505Sexual function and dysfunction studiesSchizophrenia research and treatmentSexuality, Behavior, and Technology

The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.

Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients

Montejo-gonzàlez, Angel L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., Derecho, J., Franco, M., Gomez, M. J., Macias, J. A., Martin, T., Perez, V, Sanchez, J. M., Sanchez, S., Vicens, E.·1997·Journal of Sex & Marital Therapy
DOI 10.1080/00926239708403923
Open this paper in CoChat — free account

Abstract

The authors analyzed the incidence of sexual dysfunction (SD) with different selective serotonin reuptake inhibitors (SSRIs; fluoxetine, fluvoxamine, paroxetine, and sertraline) and hence the qualitative and quantitative changes in SD throughout time in a prospective and multicenter study. Outpatients (192 women and 152 men; age = 39.6 +/- 11.4 years) under treatment with SSRIs were interviewed with an SD questionnaire designed for this purpose by the authors and that included questions about the following: decreased libido, delayed orgasm or anorgasmia, delayed ejaculation, inability to ejaculate, impotence, and general sexual satisfaction. Patients with the following criteria were included: normal sexual function before SSRI intake, exclusive treatment with SSRIs or treatment associated with benzodiazepines, previous heterosexual or self-erotic current sexual practices. Excluded were patients with previous sexual dysfunction, association of SSRIs with neuroleptics, recent hormone intake, and significant medical illnesses. There was a significant increase in the incidence of SD when physicians asked the patients direct questions (58%) versus when SD was spontaneously reported (14%). There were some significant differences among different SSRIs: paroxetine provoked more delay of orgasm or ejaculation and more impotence than fluvoxamine, fluoxetine and sertraline (chi 2, p < .05). Only 24.5% of the patients had a good tolerance of their sexual dysfunction. Twelve male patients who suffered from premature ejaculation before the treatment preferred to maintain delayed ejaculation, and their sexual satisfaction, and that of their partners, clearly improved. Sexual dysfunction was positively correlated with dose. Patients experienced substantial improvement in sexual function when the dose was diminished or the drug was withdrawn. Men showed more incidence of sexual dysfunction than women, but women's sexual dysfunction was more intense than men's. In only 5.8% of patients, the dysfunction disappeared completely within 6 months, but 81.4% showed no improvement at all by the end of this period. Twelve of 15 patients experienced total improvement when the treatment was changed to moclobemide (450-600 mg/day), and 3 of 5 patients improved when treatment was changed to amineptine (200 mg/day).

Overview

Integrity signals

Registry

Crossref · 10.1080/00926239708403923

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 62

  1. Barnes T, 1979, Br J Med, 6, 596
  2. Merino MJ, 1995, Rev Asoc ESP Neuropsiqu, XV, 54, 431
  3. Settle EC, 1992, J Clin Psychiatry, 10, 48
  4. Buffom J, 1982, J Psychoactive Drugs, 14, 4
  5. Nofzinger, EA, Thase, MEReynolds, CF. Antidepressants and sexual function in depressed men. New research program and abstracts of the 146th Annual Meeting of the American Psychiatric Association. May261993, San Francisco, California. pp.174Washington, DC: American Psychiatric Association. Abstract NR7456
  6. Cohn CK, 1990, J Clin Psychiatry, 51, 18
  7. Patterson WM, 1993, J Clin Psychiatry, 54, 71
  8. Flores MP, 1994, Anales de Psiquiatría, 10, 58
  9. Aizenberg D, 1991, J Clin Psychiatry, 52, 461
  10. Medell JC, 1989, J Clin Psychopharmacol, 9, 63
  11. Cohen A, 1992, J Clin Psychiatry, 53, 174
  12. King VL, 1993, Am J Psychiatry, 150, 984
  13. Neill JR, 1991, Am J Psychiatry, 148, 1603
  14. Chiang PH, 1994, Kao-Hsiung I Hsueh KO Hsueh Tsa Chih [Kaohsiung Journal of Medical Sciences], 10, 287
  15. 10.1192/bjp.151.1.107 · DOI
  16. Shen WW, 1983, J Reprod Med, 28, 497
  17. Herman JB, 1990, J Clin Psychiatry, 51, 25
  18. Musher JS, 1990, Am J Psychiatry, 147, 948
  19. Montejo, AL, Llorca, G.Izquierdo, JA. Sexual dysfunction with SSRIs: A comparative analysis. Abstracts of 149th Annual Meeting of the American Psychiatric Association. May1996, New York. pp.266–267. Washington, DC: American Psychiatric Association.
  20. McGilp Rm, 1993, J Drug Dev, 5, 265
  21. Zemishlany, Z. The effects of methylenedioxy-methanphetamine (“Ecstasy”) on human sexual function. Abstracts of the 149th Annual Meeting of the American Psychiatric Association. May1996, New York. pp.265Washington, DC: American Psychiatric Association.
  22. Zajecka J, 1991, J Clin Psychiatry, 52, 66
  23. Pollack MH, 1987, J Clin Psychiatry, 48, 3
  24. Jacobsen FM, 1995, Psychiatric Times, 12, 38
  25. de Castro RM, 1985, Am J Psychiatry, 142, 783
  26. McCormick S, 1990, J Clin Psychiatry, 51, 383
  27. Cohen A, 1992, J Clin Psychiatry, 53, 174
  28. Price J, 1990, J Clin Psychiatry, 51, 32
  29. Hollander E, 1992, J Clin Psychiatry, 53, 207
  30. Jacobsen FM, 1992, J Clin Psychiatry, 53, 119
  31. Balon R, 1993, J Clin Psychiatry, 54, 161
  32. Singh A, 1995, J Serotonin Res, 4, 283
  33. Jacobsen, FM. A double-blind placebo-controlled trial of yohimbine for treatment of SRI-induced sexual dysfunction. Abstracts of the 149th Annual Meeting of the American Psychiatric Association. May1996, New York. pp.266Washington, DC: American Psychiatric Association.
  34. Nessel MA, 1994, Am J Psychiatry, 151, 453
  35. Balogh S, 1992, J Clin Psychiatry, 53, 212
  36. Gitlin MJ, 1995, J Clin Psychiatry, 56, 124
  37. Yager J, 1986, J Clin Psychiatry, 47, 210
  38. Segraves RT, 1987, Am J Psychiatry, 144, 1243
  39. Walker PW, 1993, J Clin Psychiatry, 54, 459
  40. Sovner R, 1983, J Clin Psychiatry, 44, 345
  41. Feder R, 1991, J Clin Psychiatry, 152, 163
  42. Goldbloom DS, 1991, J Clin Psychiatry, 52, 261
  43. Segraves RT, 1992, J Clin Psychiatry, 10, 48
  44. Balon R, 1993, J Clin Psychiatry, 54, 209
  45. Cohn CK, 1990, J Clin Psychiatry, 51, 18
  46. Forster P, 1994, Am J Psychiatry, 151, 1523
  47. Wise TN, 1994, J Clin Psychiatry, 55, 417
  48. Zohar J, 1994, J Clin Psychiatry, 55, 86
  49. Aldrich, A. Retrospective review of psychotropic-induced sexual dysfunction in women. Abstracts of the 149th Annual Meeting of the American Psychiatric Association. May1996, New York. pp.266Washington, DC: American Psychiatric Association.
  50. 10.3109/01674828509085268 · DOI
  51. Magnus RV, 1977, Dis Nerv Syst, 38, 317
  52. Sangal R, 1985, Am J Psychiatry, 142, 1223
  53. Lydiard Rib, 1987, Am J Psychiatry, 144, 254
  54. Yeragani VK, 1988, Am J Psychiatry, 145, 531, 10.1176/ajp.145.4.531 · DOI
  55. Segraves RT, 1987, Am J Psychiatry, 144, 1240
  56. Beasley CM, 1990, Psyche pharmacol Bull, 26, 18
  57. Fahrer, R, Nazar, JSuarez, M. 1992. Efficacy and tolerance of moclobemide in 120 patients with depressive syndrome. Therapeutic advantages of moclobemide rima reversible inhibition of MAO-A: Proceedings of the Sixth European Congress of the Association of European Psychiatry. November1992, Barcelona, Spain.
  58. Schweitzer I, 1989, Int J Clin Pharm Res, 9, 111
  59. Harrison WM, 1985, Psychopharmacol Bull, 21, 85
  60. Warneke L, 1994, J Clin Psychiatry, 55, 216
  61. Schiavi RC, 1992, J Clin Psychiatry, 10, 19
  62. Wise TN, 1992, J Clin Psychiatry, 10, 11

Cited by

Sorted by citations

See all 505

Related

See all

Metadata

Authors
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., Derecho, J., Franco, M., Gomez, M. J., Macias, J. A., Martin, T., Perez, V, Sanchez, J. M., Sanchez, S., & Vicens, E.
ORCID
Venue
Journal of Sex & Marital Therapy
Publisher
Informa UK Limited
Published
1997-09
Volume
23
Issue
3
Pages
176-194
ISSN
  • 0092-623X (ISSN-L)
  • 1521-0715
DOI
10.1080/00926239708403923
OpenAlex
W2126074061
Cited by
505
References
114
Citations by year
2026: 5 · 2025: 10 · 2024: 19 · 2023: 12 · 2022: 15 · 2021: 14 · 2020: 12 · 2019: 22 · 2018: 10 · 2017: 10 · 2016: 20 · 2015: 12 · 2014: 15 · 2013: 32 · 2012: 21
FWCI
13.82
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Sex & Marital Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
Keywords
sexual dysfunction, selective serotonin reuptake inhibitors, fluoxetine, paroxetine, sertraline, fluvoxamine, anorgasmia, delayed ejaculation, erectile dysfunction, low libido, sexual satisfaction, drug dosing, moclobemide, amineptine, antidepressant side effects, sex differences
MeSH terms
Adult, Female, Fluoxetine, Humans, Male, Middle Aged, Prospective Studies, Surveys and Questionnaires, Severity of Illness Index, 1-Naphthylamine, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sexual Dysfunctions, Psychological, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review